Daewon Pharmaceutical Co., Ltd.
Daewon Pharmaceutical Co., Ltd. (KRX: 003220) is trading at ₩8,190.00, about ₹591 at today's KRW/INR rate, as of 8 Oct 2026, 2:30 AM ET, down 0.73% today. Daewon Pharmaceutical is not currently available to trade on Paasa; this page shows its price, statistics and the Indian tax treatment for information.
Quote
Today's low
₩8,050.00
Today's high
₩8,250.00
52 week low
₩7,060.00
52 week high
₩13,670.00
003220 opened at ₩8,090.00, closed previously at ₩8,250.00, and has traded between ₩7,060.00 and ₩13,670.00 over the past 52 weeks.
About
Established in 1958 and headquartered in Seoul, South Korea, Daewon Pharmaceutical Co., Ltd. is a well-regarded pharmaceutical enterprise specializing in the development, manufacturing, and distribution of a comprehensive range of medications and medical supplies within the South Korean market. Its extensive product portfolio targets diverse therapeutic fields, encompassing cardiovascular, respiratory, anti-infective, oncology, and neuropsychiatric conditions. Key offerings include Oramin-F Soft Cap, a notable multivitamin; Pelubi Tablet, an NSAID specifically formulated for pain management; Freefol-MCT Inj., a microemulsion propofol designed to prevent exogenous bacterial infections; Megex-I Susp, a medication that supports the nutritional needs of cancer patients experiencing subalimentation; Trigel Susp, an effective treatment for gastritis and duodenal ulcers; and Renamezin Cap, a spherical carbonaceous adsorbent for managing chronic kidney disease. Furthermore, Daewon Pharmaceutical extends its global footprint by exporting its products to approximately 45 countries, predominantly across Asia, Central and South America, and the Middle East.
Key statistics
Avg. volume
109.73K
Market cap
₩175.54B
P/E Ratio
66.81
Price-to-sales ratio
0.29
Enterprise value
₩396.18B
Free cash flow yield
5.38%
Debt-to-equity ratio
0.71
Return on equity
-0.52%
ROIC
-0.49%
Beta
0.18
Dividend yield
3.05%
Last dividend
₩250.00
Financial overview
Revenue
₩605.64B
Earnings per share
-₩64.37
Free cash flow
₩13.78B
Net profit margin
0.43%
Gross margin
44.88%
EBITDA
₩27.23B
Revenue growth
1.25%
Similar securities
This is not an investment recommendation
Daewon Pharmaceutical for Indian investors
Daewon Pharmaceutical is listed on the Korea Exchange. It is not currently available to trade on Paasa; the figures on this page are for information, and the tax notes below apply to Indian residents who hold it.
Taxes on Daewon Pharmaceutical for Indian residents
Trading and limits
- Trading hours
- 9:00 am – 3:30 pm KST
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- Slab rateDividends are taxed at your slab rate in India. Daewon Pharmaceutical’s current yield is 3.05%.Dividend tax explained
FAQs
Can I buy Daewon Pharmaceutical on Paasa?
Daewon Pharmaceutical (003220) has been listed on the Korea Exchange since 2005, in the Drug Manufacturers - Specialty & Generic industry. Daewon Pharmaceutical is not currently available to trade on Paasa; the figures on this page are for information. Indian residents who hold it through another broker still declare it under the rules below.
How much does one Daewon Pharmaceutical share cost in rupees?
One Daewon Pharmaceutical share is ₩8,190.00 — about ₹591 at a KRW/INR rate of 0.0722 on 8 Oct 2026. Both the Daewon Pharmaceutical price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for investing abroad from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability.
How are gains on Daewon Pharmaceutical shares taxed in India?
Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the KRW/INR rate on the purchase and the sale date, so the rupee move counts alongside the Daewon Pharmaceutical price.
Does Daewon Pharmaceutical pay a dividend, and how is it taxed in India?
Yes. Daewon Pharmaceutical pays a dividend and the current yield is 3.05%; the last declared dividend was ₩250.00 per share, about ₹18.04. Dividends are taxed at your slab rate in India.
When does KRX trade, in Indian time?
The Korea Exchange trades 5:30 am – 12:00 pm IST in Indian time.
Do I have to declare Daewon Pharmaceutical shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. The holding is reported with its cost and its closing value.
Does the rupee rate affect what I make on Daewon Pharmaceutical?
Yes. Daewon Pharmaceutical is priced in KRW, so your rupee outcome combines the KRW move with the KRW/INR move between the day you remit and the day you convert back.